Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2014.03.037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Effects of Metformin on Weight Loss, Cardiovascular Health, and Longevity.
Cardiol Rev
December 2024
Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY.
Metformin, a biguanide derived from Galega officinalis, was first synthesized by Werner and Bell in 1922. Metformin was approved for the treatment of diabetes by the US Food and Drug Administration in 1994. It has since become the most widely used oral antidiabetic agent.
View Article and Find Full Text PDFSurvival benefit of metformin use according to cancer diagnosis in diabetic patients with metabolic syndrome.
Prev Med Rep
December 2024
Department of Statistics and Actuarial Science, Soongsil University, South Korea.
Background: Metabolic syndrome (MetSyn) is a disease cluster causing cardiovascular disease, cancer, and high mortality. Metformin is the most common antidiabetic agent inhibiting the tumorigenesis and insulin resistance of MetSyn. We describe the association between metformin intake and survival of patients with type 2 diabetes mellitus (T2DM) and MetSyn, according to the presence of cancer.
View Article and Find Full Text PDFType II diabetes and metformin use does not affect colorectal cancer prognosis.
Int J Cancer
November 2024
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Previous studies on the impact of metformin and colorectal cancer (CRC) outcomes have been limited by small size and confounding by indication, yielding inconsistent results. The aim of this study was to assess whether diabetes and pre-diagnostic metformin use influence CRC prognosis. The study was performed using the Colorectal Cancer Data Base Sweden, a register-linkage originating from the Swedish Colorectal Cancer Register with linkage to national health care registers and demographic registers.
View Article and Find Full Text PDFStopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study.
Am J Kidney Dis
November 2024
Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee. Electronic address:
Article Synopsis
- Current guidelines advise against metformin for patients with advanced kidney impairment, despite limited evidence supporting this recommendation, prompting an observational study to compare outcomes of continuing versus stopping metformin after developing stage 4 chronic kidney disease (CKD).
- The study found that out of 4,278 metformin users with incident CKD stage 4, those who stopped taking the medication experienced a significantly lower 3-year survival rate compared to those who continued, although the incidence of major cardiovascular events was similar between the two groups.
- The findings suggest that ongoing metformin use may be beneficial for patients with advanced kidney impairment, although the study does acknowledge potential limitations due to residual confounding factors.
Metformin associates with higher myocardial perfusion reserve and survival in type 2 diabetes mellitus patients.
Sci Rep
November 2024
Department of Biomedical Imaging Science, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, LS2 9JT, UK.
Metformin is an antihyperglycemic used to treat type 2 diabetes mellitus (T2DM). Patients with T2DM are at increased risk of cardiovascular disease. We explored the association between metformin use and cardiovascular magnetic resonance (CMR) derived stress myocardial blood flow (MBF), myocardial perfusion reserve (MPR) and major adverse cardiovascular events (MACE; all cause death, MI, stroke, heart failure hospitalisation and coronary revascularisation) in patients with T2DM.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!